IS7811A - Aðferðir og prófefni til að meðhöndla sjúkdóma ogkvilla sem tengjast auknu magni af bólguvaldandi frumuboðum - Google Patents

Aðferðir og prófefni til að meðhöndla sjúkdóma ogkvilla sem tengjast auknu magni af bólguvaldandi frumuboðum

Info

Publication number
IS7811A
IS7811A IS7811A IS7811A IS7811A IS 7811 A IS7811 A IS 7811A IS 7811 A IS7811 A IS 7811A IS 7811 A IS7811 A IS 7811A IS 7811 A IS7811 A IS 7811A
Authority
IS
Iceland
Prior art keywords
diseases
treatment
methods
disorders associated
increased levels
Prior art date
Application number
IS7811A
Other languages
English (en)
Inventor
Manivasakam Palaniyandi
Smith Brendan
Fong Jason
A. Auspitz Benjamin
James Nichols M.
Keith Curtis
R. Zimmermann Grant
B. Brasher Bradley
Sachs Noah
W. Chappell Todd
Grau Daniel
Roydon Jost-Price Edward
Original Assignee
Combinatorx, Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32074779&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS7811(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Combinatorx, Incorporated filed Critical Combinatorx, Incorporated
Publication of IS7811A publication Critical patent/IS7811A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IS7811A 2002-09-24 2005-04-19 Aðferðir og prófefni til að meðhöndla sjúkdóma ogkvilla sem tengjast auknu magni af bólguvaldandi frumuboðum IS7811A (is)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US41304002P 2002-09-24 2002-09-24
US41726102P 2002-10-09 2002-10-09
US42742402P 2002-11-19 2002-11-19
US42752602P 2002-11-19 2002-11-19
US46475303P 2003-04-23 2003-04-23
PCT/US2003/030156 WO2004030618A2 (en) 2002-09-24 2003-09-24 Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines

Publications (1)

Publication Number Publication Date
IS7811A true IS7811A (is) 2005-04-19

Family

ID=32074779

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7811A IS7811A (is) 2002-09-24 2005-04-19 Aðferðir og prófefni til að meðhöndla sjúkdóma ogkvilla sem tengjast auknu magni af bólguvaldandi frumuboðum

Country Status (12)

Country Link
EP (1) EP1553955A4 (is)
JP (1) JP2006503905A (is)
AR (1) AR041386A1 (is)
AU (1) AU2003299196A1 (is)
BR (1) BR0314713A (is)
CA (1) CA2509526A1 (is)
HR (1) HRP20050355A2 (is)
IS (1) IS7811A (is)
MX (1) MXPA05003152A (is)
NO (1) NO20051669L (is)
TW (1) TW200422042A (is)
WO (1) WO2004030618A2 (is)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05008649A (es) * 2003-02-14 2005-11-23 Combinatorx Inc Terapia de combinacion para el tratamiento de desordenes inmunoinflamatorios.
AU2004275777A1 (en) * 2003-09-24 2005-04-07 Combinatorx, Incorporated Therapeutic regimens for administering drug combinations
CA2566861A1 (en) * 2004-05-17 2005-12-08 Combinatorx, Incorporated Methods and reagents for the treatment of immunoinflammatory disorders
BRPI0517847A (pt) * 2004-11-19 2008-10-21 Organon Nv combinação, usos de um inibidor de reabsorção de serotonina seletiva e de um antagonista do receptor de glicocorticóide, e, método para o tratamento de um indivìduo de uma espécie vertebrada sofrendo de depressão ou um distúrbio relacionado
AU2011236053B2 (en) * 2004-11-19 2014-06-26 Merck Sharpe & Dohme B.V. Drug combination comprising a selective serotonin reuptake inhibitor and a glucocorticoid receptor antagonist for the treatment of depression
ATE473735T1 (de) * 2005-04-13 2010-07-15 Astion Dev As Beta-2 adrenoceptor agonisten zur behandlung von bindegewebserkrankungen der haut
JP4832806B2 (ja) * 2005-06-03 2011-12-07 久光製薬株式会社 経皮投与製剤
TW200711649A (en) * 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
WO2008031014A1 (en) * 2006-09-08 2008-03-13 Ore Pharmaceuticals Inc. Method for reducing or alleviating inflammation in the digestive tract
US20080064709A1 (en) * 2006-09-11 2008-03-13 Duke University Methods and compositions for the treatment of vascular depression
GB0701171D0 (en) * 2007-01-22 2007-02-28 Imp Innovations Ltd Compositions and uses thereof
WO2010098230A1 (ja) * 2009-02-27 2010-09-02 久光製薬株式会社 経皮投与製剤
PT117765B (pt) * 2022-01-28 2025-04-04 Faculdade De Farmacia Da Univ De Lisboa Formulação tópica de fluvoxamina para o tratamento de psoríase
TW202423434A (zh) * 2022-10-07 2024-06-16 瑞士商歐庫利斯營運股份有限公司 mTOR抑制劑的點眼劑微懸液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU674292B2 (en) * 1991-10-15 1996-12-19 Immunex Corporation Methods and compositions for treating allergic reactions
GB9603137D0 (en) * 1996-02-15 1996-04-17 Merck Sharp & Dohme Therapeutic agents
DE69735656T2 (de) * 1996-07-15 2006-08-24 Alza Corp., Mountain View Vorrichtung zur transdermalen Verabreichung von Fluoxetin
PL336464A1 (en) * 1997-03-18 2000-06-19 Basf Ag Method of and compositions for modulating reactivity in respect to corticosteroids i
US6281248B1 (en) * 2000-02-16 2001-08-28 Magda Abdel Fattah Ahmed Composition for treating asthma
IL139975A0 (en) * 2000-11-29 2002-02-10 Univ Ramot Anti proliferative drugs

Also Published As

Publication number Publication date
TW200422042A (en) 2004-11-01
AU2003299196A1 (en) 2004-04-23
CA2509526A1 (en) 2004-04-15
JP2006503905A (ja) 2006-02-02
EP1553955A4 (en) 2008-11-05
MXPA05003152A (es) 2006-04-27
AR041386A1 (es) 2005-05-18
NO20051669L (no) 2005-06-10
HRP20050355A2 (en) 2005-10-31
BR0314713A (pt) 2005-07-26
EP1553955A2 (en) 2005-07-20
WO2004030618A2 (en) 2004-04-15
WO2004030618A3 (en) 2005-04-07

Similar Documents

Publication Publication Date Title
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
DK1888033T3 (da) Fremgangsmåde og sammensætning til behandling af inflammatoriske sygdomme
CY2021009I2 (el) Αντισωματα αντι-ρ-σελεκτινης και μεθοδοι χρησης αυτων στην αντιμετωπιση φλεγμονωδων νοσων
IL183827A0 (en) Novel heterocyclic compounds useful for the treatment of inflammatory and allergic disorders
DK1889065T3 (da) Metoder til diagnostisering og behandling af sygdomme med en autoimmun- og/eller inflammationskomponent
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
DK1755743T3 (da) Beta-hydroxybutyrat og derivater til behandling af depression og angst
SI1608374T1 (sl) Derivati 2-fenoksi- in 2-fenilsulfonamida s CCR3 antagonistično aktivnostjo za zdravljenje astme in drugih vnetnih ali imunoloških obolenj
DK1626728T3 (da) Oxiderede lipider og anvendelse heraf ved behandling af inflammatoriske sygdomme og forstyrrelser
DK1765322T3 (da) Retinal-derivater og fremgangsmåder til anvendelse deraf i behandlingen af synsforstyrrelser
DK1805312T3 (da) Fremgangsmåder og midler til fremstilling af hyaluronan
IS7811A (is) Aðferðir og prófefni til að meðhöndla sjúkdóma ogkvilla sem tengjast auknu magni af bólguvaldandi frumuboðum
DK1663978T3 (da) Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
DK2308507T3 (da) Fremgangsmåder til behandling af præeklampsi
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
PL381765A1 (pl) Konstrukty wiążące i sposoby ich zastosowania
IL180251A0 (en) Methods and reagents for the treatment of metabolic disorders
EP1811935A4 (en) HEAT-HARDENED GEL AND MANUFACTURING METHOD
EP1746902A4 (en) MULTI-LECTIN AFFINITY CHROMATOGRAPHY AND USES THEREOF
DK1487828T3 (da) Morpholinyl-urea-derivater til anvendelse til behandling af inflammatoriske sygdomme
ITMI20050704A1 (it) Dispositivo semiconduttore e metodo di produzione dello stesso
DK1701944T3 (da) 2-(amino-substituerede)-4-aryl-pyramidiner og relaterede forbindelser til behandling af inflammationssygdomme
DK1478438T3 (da) Fremgangsmåder og sammensætninger til behandling af astma
DK1952103T3 (da) Fremgangsmåde til at veje med flere vejeceller
DK1589973T4 (da) Formulering og fremgangsmåder til behandling af thrombocytæmi